THE ROLE OF PRO-INFLAMMATORY AND ANTI-INFLAMMATORY CYTOKINES DURING COVID-19 IN PATIENTS WITH CHRONIC ENT DISEASE
Keywords:
Patients with ENT diseases, COVID-19, cytokinesAbstract
Objective: The aim of the study was to evaluate the serum levels of regulatory cytokines in ENT patients hospitalized with moderate and severe COVID-19.
Materials and Methods: 84 patients with confirmed coronavirus infection were taken under observation. Among them, 16 (19.04%) patients had a mild course, 44 (52.4%) patients had an average course, and 24 (28.6%) patients had a severe course. The diagnosis of COVID-19 was established based on the detection of SARS-CoV-2 RNA by PCR in swabs taken from the nasopharynx and oropharynx. Serum levels of cytokines (IL-1β, IL-4, IL-6, IFNα, and IFNγ) were measured by IFA using kits from Vector Best OJSC (Novosibirsk, Russia).
Results: showed that the levels of anti-inflammatory cytokines (IL-1β and IL-6) and anti- inflammatory (IL-4) cytokines are dramatically increased in patients with ENT diseases against the background of COVID-19. Also, high levels are more common in severe COVID-19. Interferons in COVID-19 have multidirectional synthesis: IFNα decreases and IFNγ increases.
Conclusions. The state of immunodeficiency of COVID-19, which develops due to lymphopenia in patients with ENT diseases, is the main pathogenetic mechanism of the "cytokine storm" syndrome when the synthesis of pro-inflammatory (IL-1β and IL-6) is increased. and pro-inflammatory (IL-4) cytokines. In addition, the maximum value of these cytokines was recorded in patients with severe COVID-19. The synthesis of type I and II interferons against the background of COVID-19 in patients with ENT diseases changed depending on the severity of the disease. In moderately severe patients, the level of IFNα decreased by 1.4 times, and in severe patients by 1.9 times. However, the level of IFNg was 2 times higher in moderate patients than in controls, and 2.3 times higher in severe patients.
References
Алексеева Е.И., Тепаев Р.Ф., Шилькрот И.Ю., Дворяковская Т.М., Сурков А.Г.,
Криулин И.А. COVID-19-индуцированный ≪цитокиновый шторм≫ — особая форма синдрома активации макрофагов. Вестник РАМН. 2021;76(1):51–66.doi: https://doi.org/10.15690/vramn1410
Клыпа Т.В., Бычинин М.В., Мандель И.А., Андрейченко С.А., Минец А.И., Колышкина Н.А., Троицкий А.В. Клиническая характеристика пациентов с COVID+19, поступающих в отделение интенсивной терапии. Предикторы тяжелого течения//Клиническая практика. 2020., Т.11, №2., С.6-20
Муркамилов И. Т. Цитокиновый статус при новой коронавирусной болезни (COVID-19) //Вестник Кыргызско-Российского Славянского университета. – 2020. – Т. 20. – №. 9. – С. 55-65.
Петров В.И., Амосов А.А, Герасименко А.С., Шаталова О.В., Пономарева А.В., Акинчиц А.Н., Кулакова И.С., Горбатенко В.С. Механизмы развития цитокинового шторма при COVID-19 и новые потенциальные мишени фармакотерапии. Фармация ифармакология. 2020;8(6):380-391. DOI:10.19163/2307-9266-2020-8-6-380-391
Романов БК. Коронавирусная инфекция COVID-2019. Безопасность и риск фармакотерапии. 2020;8(1):3–8. https://doi.org/10.30895/2312-7821-2020-8-1-3-8
Ткаченко О. Ю. и др. Прогнозирование течения вирусной пневмонии при COVID-19 с помощью шкалы «цитокинового шторма» //Терапия. – 2021. – Т. 7. – №. 6. – С. 42-50.
Сушенцева Н. Н., Попов О. С., Апалько С. В.,Анисенкова А. Ю., Азаренко С. В., Сманцерев К. В., Хоботников Д. Н., Гладышева Т. В., Минина Е. В., Стрелюхина С. В., Уразов С. П., Павлович Д., Фридман С. Р., Щербак С. Г. Биобанк COVID-19: особенности цитокинового профиля. Кардиоваскулярная терапия и профилактика. 2020;19(6):2729. doi:10.15829/1728-8800-2020-2729
Rizayev A. Jasur, Shodmonov A. Akhrorbek, Rajabiy A. Muzayyana. The role of the implant stability coefficient in dental implantation// Journal of Biomedicine and Practice. 2023, vol. 8, issue 2, pp.10-14
ЖА Ризаев, АС Кубаев, АА Абдукадиров Cостояние риномаксиллярного комплекса и его анатомо-функциональных изменений у взрослых больных с верхней микрогнатией // Журнал теоретической и клинической медицины, 162-165, 2020
Shalhoub S, Farahat F, Al-Jiff ri A, Simhairi R, Shamma O, SiddiqiN, Mushtaq A. IFN-α2a or IFN-β1a in combination withribavirin to treat Middle East respiratory syndrome coronaviruspneumonia: a retrospective study.J.AntimicrobChemother.2015;70(7):2129- 32.https://doi.org/10.1093/jac/dkv085
Henderson LA, Canna SW, Schulert GS, et al. On the Alert for Cytokine Storm: Immunopathology in COVID‐19. Arthritis Rheumatol.2020;72:1059–1063. doi: https://doi.org/10.1002/art.41285
McGonagle D, Sharif K, O’Regan A, et al. The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease. Autoimmun Rev.2020;19:102537. doi: https://doi.org/10.1016/j.autrev.2020.102537
Jamilloux Y, Henry T, Belot A, et al. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anticytokine interventions. Autoimmun Rev. 2020;19:102567. doi:https://doi.org/10.1016/j.autrev.2020.102567
Tay MZ, Poh CM, Renia L, et al. The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol.2020;20:363–374. doi: https://doi.org/10.1038/s41577-020- 0311-841. Netea MG, Balkwill F, Chonchol M, et al. A guiding map for inflammation. Nat Immunol. 2017;18:826–831. doi: https://doi.org/10.1038/ni.3790
Sarzi-Puttini P, Giorgi V, Sirotti S, et al. COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? ClinExpRheumatol. 2020;38:337–342.
Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. The Lancet. 2020;395:1033–1034. doi: https://doi.org/10.1016/S0140- 6736(20)30628-01455. doi: https://doi.org/10.1182/blood-2017-12-820852
Giamarellos-Bourboulis EJ, Netea MG, Rovina N, et al. Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure. Cell Host Microbe. 2020;27:992–1000.e3. doi:https://doi.org/10.1016/j.chom.2020.04.009
Herold T, Jurinovic V, Arnreich C, et al. Level of IL-6 predicts respiratory failure in hospitalized symptomatic COVID-19 patients. Infectious Diseases (except HIV/AIDS) 2020. doi: https://doi.org/10.1101/2020.04.01.20047381
Makris S, Paulsen M, Johansson C. Type I Interferons as Regulators of Lung Inflammation. Front Immunol. 2017;8:259. doi: https://doi.org/10.3389/fimmu.2017.00259
Azkur AK, Akdis M, Azkur D, et al. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy. 2020;75:1564–1581. doi:https://doi.org/10.1111/all.14364
Channappanavar R, Fehr AR, Vijay R, et al. Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice. Cell Host Microbe. 2016;19:181–193. doi: https://doi.org/10.1016/j.chom.2016.01.007
Paules CI, Marston HD, Fauci AS. Coronavirus infections— more than just the common cold. JAMA. 2020;323(8):707–8. https://doi.org/10.1001/jama.2020.0757
Trouillet-Assant S, Viel S, Gaymard A, et al. Type I IFN immunoprofiling in COVID-19 patients. J Allergy ClinImmunol. 2020;146:206–208.e2. doi: https://doi.org/10.1016/j.jaci.2020.04.029
Hadjadj J, Yatim N, Barnabei L, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369:718–724. doi: https://doi.org/10.1126/science.abc6027
Coperchini F, Chiovato L, Croce L, et al. The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor Rev. 2020;53:25–32. doi: https://doi.org/10.1016/j.cytogfr.2020.05.003
